Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 424 participants.

Also called NCT02739984

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 424 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02739984
  • EudraCT 2015-004711-21
Other papers using this trial's data
  • Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study Diabetologia, 2019-06 DOI, PubMed 30953107, PMC6509076 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Canada, Italy, Mexico, Poland, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02739984. Randomized; triple masking; primary purpose treatment. Start 2016-05-17 (actual); primary completion 2017-08-03 (actual). Results posted on 2018-08-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
Acronym
BANTING
Condition
Hypercholesterolemia
Condition
Mixed Dyslipidemia
Intervention (Biological)
Evolocumab
Intervention (Drug)
Placebo to Evolocumab
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct02739984
Content hash
c691cc4fe6116d29bd01d0f7afc7ecf75285693af243764824c6960a18823919